Step 2/3
Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia caused by vessel trauma from the balloon angioplasty. Find news and video content on DCBs
October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT ...
October 30, 2023 
September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry ...
September 14, 2023 
September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease ...
September 11, 2023 
July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized ...
July 14, 2023 
May 30, 2023 — Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan ...
May 30, 2023 
May 30, 2023 — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for ...
May 30, 2023 
May 12, 2023 — The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s novel ...
May 12, 2023 
May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the ...
May 04, 2023 
April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month ...
April 28, 2023 
March 14, 2023 —MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo ...
March 14, 2023